Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04936256 · ClinicalTrials.gov registry record
Evaluation of Binocular Visual Acuity and Refractive Stability in the Alcon Clareon Intraocular Lens
A clinical trial, sponsored by Gainesville Eye Associates.
- Completed
- Registry status
- 31
- Enrollment target
NCT04936256: Completed study, sponsored by Gainesville Eye Associates.
NCT04936256 is a clinical trial that has completed, run by Gainesville Eye Associates. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04936256 has completed, sponsored by Gainesville Eye Associates.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
The objective is to evaluate refractive stability (spherical equivalent change ≤ 0.50D from 1-month to 3-months).
Primary Outcome
Refractive stability (spherical equivalent change ≤ 0.50D from 1-month to 3-months)
Interventions
- DEVICE Clareon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2022-07-28 |
What the finished NCT04936256 record still lists
NCT04936256 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 31 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Clareon is the first listed.
NCT04936256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04936256 about?
NCT04936256 is a clinical study titled "Evaluation of Binocular Visual Acuity and Refractive Stability in the Alcon Clareon Intraocular Lens". The objective is to evaluate refractive stability (spherical equivalent change ≤ 0.50D from 1-month to 3-months).
What is the current status of trial NCT04936256?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2021-07-02. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT04936256?
The interventions under investigation include: Clareon (DEVICE).
Who is sponsoring clinical trial NCT04936256?
This trial is sponsored by Gainesville Eye Associates, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI